Eisai Launches Its First Drug In Russia, A Breast-Cancer Treatment
This article was originally published in PharmAsia News
Eisai said it has launched its first drug in Russia, its Halaven (eribulin) breast-cancer drug, already approved in 50 other countries.
You may also be interested in...
Potentially transformative treatments for severe asthma, COPD and osteoarthritis are among some of the below-the-radar projects the Swiss major is advancing, according to Vas Narasimhan.
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.
In the second segment of a two-part article on transparency provisions for the new EU clinical trial portal, a senior Merck executive explains how the company will ensure that commercially sensitive information and personal data in its clinical trial applications are not made public.